Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A clinico-pathological study of malignant lymphoma in Jamaica was undertaken to examine the disease pattern in a predominantly negro population of West African origin. During a 9-year period (1958-66) 260 histologically verified cases of malignant lymphoma were encountered. The distribution of the different histological types was as follows: Hodgkin's disease 50.9%, lymphosarcoma 33%, reticulum cell sarcoma 14.2%, giant follicular lymphoma 1.9%. No cases of Burkitt's tumour were encountered.This study indicates that malignant lymphoma is not uncommon in Jamaica, and that its distribution pattern is similar to that observed in Europe and North America, except for the paucity of giant follicular lymphoma, and is different from the pattern observed in parts of Africa populated by Negroes, where Burkitt's tumour is the most common type, and where Hodgkin's disease is relatively uncommon. The age and sex incidence was in general similar to other reported series, but the duration of symptoms was short. The majority of patients presented with generalised peripheral lymphadenopathy. Hepatosplenomegaly and anaemia were common on admission. The prognosis was generally poor in comparison with European and North American series due to advanced stage of disease on presentation.
 ...
PMID:Clinico-pathological study of malignant lymphoma in Jamaica. 491 67

Lymphocyte depletion Hodgkin's disease (LDHD) was diagnosed in 8 of 40 children with Hodgkin's disease treated from July 1969 to September 1976. All of the children received conventional radiotherapy and combination chemotherapy with mustine, vinblastine, procarbazine, and prednisone (MVPP). In LDHD children the disease was associated with severe anemia, splenomegaly presence of mediastinal enlargement, and dissemination at the time of diagnosis. Three children with LDHD did not achieve remission and died with uncontrolled disease. In two others, relapses occurred and led to death in one. Only three children remain in their first remission. Only 3 of 32 patients with non-LDHD relapsed and entered second remission. All 32 patients were free of disease at the time of evaluation, with mean survival of 88.2 months. We conclude that LDHD in childhood is frequently associated with clinically advanced disease and still has a bad prognosis. Alternative approaches to its therapy are needed.
 ...
PMID:Treatment of lymphocyte depletion Hodgkin's disease in children. 617 54

The distribution of transferrin receptors (TR) has been studied in a range of normal and malignant tissues using four monoclonal antibodies, BK19.9, B3/25, T56/14 and T58/1. In normal tissues TR was found in a limited number of sites, notably basal epidermis, the endocrine pancreas, hepatocytes, Kupffer cells, testis and pituitary. This restricted pattern of distribution may be relevant to the characteristic pattern of iron deposition in primary haemachromatosis. In contrast to this limited pattern of expression in normal tissue, the receptor was widely distributed in carcinomas, sarcomas and in samples from cases of Hodgkin's disease. This malignancy-associated expression of the receptor may play a role in the anaemia of advanced malignancy by competing with the bone marrow for serum iron.
 ...
PMID:Transferrin receptors in human tissues: their distribution and possible clinical relevance. 630 35

Marrow transplantation is effective treatment for a number of haematological diseases in patients under the age of 50 who have an HLA-identical sibling donor. It is generally successful when used early in the treatment of aplastic anaemia. It is the only treatment that offers long-term disease-free survival for patients with acute leukaemia who have relapsed at least once, with 10-30 per cent apparent cures. Although still somewhat controversial, it appears also to be the treatment of choice for patients with acute non-lymphoblastic leukaemia in first chemotherapy induced remission and for those with chronic myelogenous leukaemia in the chronic phase since approximately 50-60 per cent of these patients are surviving after marrow transplantation in complete remission, apparently cured. Marrow grafting is the only effective treatment for many patients with inherited immunological-deficiency diseases and certain genetic storage diseases. It is being explored for the therapy of patients with lymphoma, Hodgkin's disease, multiple myeloma, small-cell lung cancer, testicular cancer, ovarian cancer and genetic disorders of haematopoiesis. Cures of congenital Fanconi anaemia, Blackfan-Diamond anaemia, osteopetrosis, and paroxysmal nocturnal haemoglobinuria have been achieved by marrow grafting. Genetic disorders associated with haemolytic anaemia and cyclic neutropenia have been cured by marrow grafting in animals. Target disorders for marrow transplantation in humans are thalassaemia major and sickle cell disease, and, indeed, a first successful transplant for treatment of thalassaemia major has recently been described (Thomas et al, 1982). Marrow transplantation has been limited by the fact that many patients do not have HLA-identical siblings and very few have monozygotic twins. The Seattle team has now explored the use of less well-matched family member donors in more than 80 patients with leukaemia. These donors share one HLA haplotype genetically with the patient and are phenotypically identical at two of the three major HLA loci on the other HLA haplotype (Clift et al, 1979). Overall, the post-transplant survival appears more a reflection of the type and stage of the leukaemia than of the marrow donor. Patients with leukaemia grafted in relapse have a projected survival of 20-30 per cent and those transplanted in remission of 50 per cent. The incidence and severity of GVHD may not be significantly different from that of patients given HLA-identical sibling marrow grafts.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Application of bone marrow transplantation in leukaemia and aplastic anaemia. 635 79

Quantitative whole-body linear profile scans of 59Fe, obtained by a whole-body counter, conventional ferrokinetics and hematological parameters are investigated in patients (n = 208) with various hematological-oncological diseases. Linear whole-body profile scans in controls, obtained 24 h after i.v. injection of 59Fe-transferrin, give quantitative information about sites of the erythropoietic system. Early profile scans (1 h p.i.) in patients with anemia show a typical 'iron-suction' corresponding to the fast outflow of 59Fe from the blood compartment. We found no typical change of iron distribution in Hodgkin and Non-Hodgkin lymphomas, even in patients with anemia or hemolysis there was no evidence of expansion of erythropoiesis to distal marrow sites. Our investigation does not contribute to staging of patients with Hodgkin's disease. Osteomyelofibrosis is characterized by a centrifugally expanded erythropoiesis. The value of increased iron uptake 24 h p.i. in leg regions for differential diagnosis of hemolytic anemia, chronic myelocytic leukemia, and pancytopenia where a similar pattern of iron distribution is observed will be discussed. Quantitative iron kinetics with one dimensional 59Fe profile scans give additional information in patients with displaced erythropoietic system.
 ...
PMID:[Ferrokinetics in 1-dimensional whole-body profiles in hematologic diseases]. 640 12

To identify a group of patients who are likely to have specific liver damage (a risk group), 88 patients with lymphogranulomatosis were examined. The examination program included clinical studies, liver scanning, peripheral blood analysis, blood serum biochemistry, study of the bone marrow, liver biopsy in all the patients. Eleven patients manifested specific liver damage. In all the patients with liver lymphogranulomas, the disease ran an unfavourable course; they frequently demonstrated the symptoms of intoxication enlargement of the liver size, focal changes on the scanogram and concurrent damage to the bone marrow. According to the biochemical tests, high activity (over 200 U/l) of alkaline phosphatase was recorded exclusively in patients with the lymphogranulomatosis-induced liver damage. Nevertheless, none of the above-enumerated signs regarded separately cannot serve as criterion of the diagnosis of lymphogranulomatosis metastases to the liver. Analysis of the rate of association of individual clinical symptoms and laboratory findings demonstrated that the most informative were associations of high alkaline phosphatase activity and enlargement of the liver size, as well as association of thrombocytopenia and anemia. However, histological study of liver biopsies is the most reliable method of diagnosis of lymphogranulomatosis metastases to the liver, particularly in patients with clinical stages I-II, since in such patients with lymphogranulomatosis, specific liver damage runs an asymptomatic course.
 ...
PMID:[Early diagnosis of specific lesions of the liver in lymphogranulomatosis]. 649 95

Based on a case report of a 19-year-old woman with Hodgkin's disease in pregnancy and on several casuistic communications and comparative studies from the literature the problems of cytostatic therapy in pregnancy are discussed. The following conclusions may be drawn: Cytostatic therapy in varying combination seems not to be associated with a damage to the fetus, even when applied in the first trimester of pregnancy. Fetal disturbances occurred almost exclusively under a combination chemotherapy and radiation therapy. In the case observed by us a combination chemotherapy with adriblastin, vincristine and prednisone was successfully applied from the 28th week of pregnancy on. The child showed no disturbances apart from a slight degree of intrauterine growth retardation which must also be seen in connection with a severe anemia of the mother or her nicotine abuse.
 ...
PMID:[Chemotherapy for Hodgkin's disease during pregnancy--a case report]. 655 10

A case of sinus histiocytosis with massive lymphadenopathy in a boy of 13 with multiple subcutaneous tumor-like formations 0.5 to 2.5 cm in diameter is described. The general condition of the patient was not changed despite the 7-month course of the disease. Mild anemia and increased ESR were observed. Microscopically the formations presented massive "dense" infiltrates of lymphoid, plasma cells, and histiocytes-macrophages with foci of fibrosis and xanthomatosis. Since the morphological picture of sinus histiocytosis with massive lymphadenopathy may to some extent imitate the substrate of some tumor diseases of the hemopoietic and lymphoid tissues (malignant histiocytosis, histiocytosis X, lymphogranulomatosis, lymphosarcoma), their differential diagnosis is presented.
 ...
PMID:[Sinus histiocytosis with massive lymphadenopathy]. 660 46

The early diagnosis of intestinal non-Hodgkin lymphoma, stages I and II, lymphoblastic of Burkitt's type, was made by colonoscopy combined with selective radiologic visualization of the tumor in two children, ages 4 and 5. This technique is recommended in patients with abdominal pain, iron-deficiency anemia, intestinal blood loss, and an elevated sedimentation rate, when conventional radiologic and ultrasound techniques fail.
 ...
PMID:Early diagnosis of intestinal non-Hodgkin lymphoma by endoscopy. 662 65

A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29% of patients developed leukopenia of less than 3000 cells/mm3, 16% developed a thrombocytopenia of less than 100,000 cells/mm3, and 29% had an acute fall in hemoglobin of greater than or equal to 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.
 ...
PMID:Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. 668 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>